Benzinga | Apr 7, 2021 10:07AM EDT

CytomX Therapeutics Shares Down 1.1% Ahead Of Virtual Investor Event Starting 1 p.m. EDT

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody(r) technology platform, today announced that it will host a virtual investor event at 1:00 p.m. -- 3:00 p.m. ET / 10:00 a.m. -- 12:00 p.m. PT on Wednesday, April 7, 2021.



In addition to company executives, CytomX's investor event will feature presentations from and an interactive Q&A session with industry experts, including:

* John Lambert Ph.D., Queen's University Belfast, an expert on conditionally activated antibody-drug conjugates (ADCs),

* Sara M. Tolaney, M.D., Dana-Farber Cancer Institute, Harvard Medical School, an expert in breast oncology, and

* Melissa L. Johnson, M.D., Sarah Cannon Research Institute, an expert in lung cancer.

The event will focus on CytomX's Probody technology platform and the two conditionally activated ADCs, praluzatamab ravtansine (CX-2009) and CX-2029.

A live webcast will be available on the Events and Presentations section of CytomX's website, www.cytomx.com. A replay of the webcast will be available for 30 days following the presentation.